SCHEMBL5138080

SCHEMBL5138080

CCOC(=O)CCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(C(=O)OC)cc1)Cc1ccc(O)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.41
FAAH O00519 4/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
DRD2 P14416 1/20 0.36
TBXA2R P21731 1/20 0.36
ALDH1A1 P00352 1/20 0.36
P2RX3 P56373 1/20 0.36
MGAM O43451 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
POLB P06746 1/20 0.34
NAMPT P43490 2/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134492 0.86 GAA (0.44) GAAFAAHKDM4EHPGDMEN1
SCHEMBL5137399 0.85 GAA (0.43) GAAFAAHKDM4EHPGDMEN1
SCHEMBL5136216 0.84 C5AR1 (0.41)
SCHEMBL5137315 0.84 C5AR1 (0.51) GAAFAAHKDM4EHPGDMEN1
SCHEMBL4764487 0.82 C5AR1 (0.43) GAAKDM4EHPGDMEN1KMT2A
SCHEMBL5138072 0.80 C5AR1 (0.43) GAAKDM4EHPGDMEN1KMT2A
SCHEMBL5137376 0.80 C5AR1 (0.42) GAAKDM4EMEN1KMT2ADRD2
SCHEMBL5136841 0.79 C5AR1 (0.39) GAAKDM4EHPGDMEN1KMT2A
SCHEMBL649778 0.78 C5AR1 (0.40) MEN1KMT2AALDH1A1NPSR1POLB
SCHEMBL5136167 0.78 AGTR1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed